chronic disability worldwide and affects more than 20 million people in the U.S. alone. VasoLux’s technology quantitatively assesses the quality of cartilage, in vivo, in a non-destructive, minimally invasive procedure. Competing procedures and technologies, such as arthroscopy, MRI, CT, Ultrasound, OCT, and X-ray cannot provide physicians with an objective measurement capable of identifying the early progression of osteoarthritis, determining the true extent of a cartilage defect, or evaluating the quality of regenerated cartilage. Consequently, physicians lack the information needed to select the appropriate therapeutic intervention or revise their treatment plan if prior efforts have not reinvigorated the cartilage or prevented its degeneration. VasoLux’s diagnostic imaging system eliminates the subjective diagnoses of osteoarthritis, which in turn reduces inefficiencies in the health care system.